Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus
British Journal of Radiology · 2025
DOI: 10.1093/bjr/tqaf112 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, 2025. Verfasst von Akira Yamamoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Portal Vein, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objectives
To investigate the safety and long-term effectiveness of repeated ultraselective transarterial chemoembolization (rusTACE) using a 1.7-Fr-tip microcatheter in hepatocellular carcinoma (HCC) patients with portal vein tumour thrombus (PVTT).
Methods
This retrospective analysis includes HCC patients with PVTT treated with rusTACE between May 2014 and July 2022. A 1.7-Fr-tip microcatheter was used to perform rusTACE for ultraselective embolization of the tumour-feeding artery. Treatment was repeated at least 2 times within 2 months. Treatment responses, survival rates, adverse event, liver function, and tumour-feeding arteries were assessed.
Results
Twenty patients underwent rusTACE with a mean interval of 42 days between treatments. RusTACE was well-tolerated. Median survival time was 26.1 months, with 1-, 2-, 3-, and 5-year survival rates of 85.0%, 61.0%, 40.9%, and 24.6%, respectively. Complete response (CR) of PVTT was achieved in 75%. Among these, 35% maintained CR of PVTT throughout follow-up (mean, 25.0 months). Univariate analysis showed prognostic factors included Child–Pugh score 5, CR of PVTT, CR of systemic tumours at the end of rusTACE, and liver tumour burden <30%. In 17%, a peribiliary vascular plexus or communicating artery was identified as the tumour-feeding artery.
Conclusions
RusTACE is a safe and effective treatment option for HCC with PVTT in selected patients (Child–Pugh class A). RusTACE showed a high CR rate and long overall survival. The short interval between treatments and ultraselective embolization of tumour-feeding arteries contributed to favourable outcomes. Advances in knowledge RusTACE can be safely performed in HCC with PVTT and has a high local control rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.
- Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka 543-8555, Japan.
- Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.
- Department of Frontier Life-Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.
- Department of Hepatology, Kashiwara Municipal Hospital, Kashiwara 582-0005, Japan.
- Department of Radiology, Tsukazaki Hospital, Himeji 671-1227, Japan.
ORCID-Profile: Akira Yamamoto, Etsuji Sohgawa
Zitieren
APA
Yamamoto, A., Kageyama, K., Jogo, A., Sohgawa, E., Kita, R., Uchida-Kobayashi, S., Takemura, S., Tamori, A., Kaminou, T., & Miki, Y. (2025). Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus. British Journal of Radiology. https://doi.org/10.1093/bjr/tqaf112
Vancouver
Yamamoto A, Kageyama K, Jogo A, Sohgawa E, Kita R, Uchida-Kobayashi S, et al. Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus. British Journal of Radiology. 2025. doi:10.1093/bjr/tqaf112
BibTeX
@article{Yamamoto2025,
author = {Yamamoto, Akira and Kageyama, Ken and Jogo, Atsushi and Sohgawa, Etsuji and Kita, Ryuichi and Uchida-Kobayashi, Sawako and Takemura, Shigekazu and Tamori, Akihiro and Kaminou, Toshio and Miki, Yukio},
title = {Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus},
journal = {British Journal of Radiology},
year = {2025},
doi = {10.1093/bjr/tqaf112}
}
EUVIMED